Previous Page  8 / 29 Next Page
Information
Show Menu
Previous Page 8 / 29 Next Page
Page Background

Page 23

Notes:

allied

academies

Volume 2

June 11-13, 2018 | London, UK

Neurology and Neuroscience

6

th

International Conference on

Dementia is a disease of the ependymal layer: Novel theory from looking at cognitive impairment in

Multiple Sclerosis

Philip A McMillan

Doncaster and Bassetlaw NHS Trust, UK

T

he intricacies of dementia are explored in relation to varied

studies on brain atrophy in multiple sclerosis and used

to delineate the primary pathology of the latter. The theory

examines the high frequency of cognitive impairment (Jongen

2012) in Multiple Sclerosis and its early manifestation during

the disease. The fact that there is associated brain atrophy

cannot be explained by the degree of damage to neurons.

(Carlos 2015) noted a 5 to 10 times greater rate of atrophy in

Multiple Sclerosis. The cognitive changeswithMultiple Sclerosis

are then correlated embryologically to the subependymal

zone (Kazanis 2009) explaining the pathology of brain atrophy

and why we have not made more progress through research.

Our understanding of the blood CSF barrier and the brain CSF

interaction is poorly understood and probably holds the key

to the symptoms of dementia (Erikson 2013). This interaction

between the CSF and brain interstitial space is coordinated by

the ependymal and subependymal zone of the brain. This is

a novel concept that will aim to explain the links of all forms

of dementia, as well as directing fertile areas for research.

Speaker Biography

Philip A McMillan is a Consultant in the NHS with over 23 years of medical expertise.

His primary focus has been around Geriatrics and Neurological Rehabilitation

and has developed unique perspectives on the capacity of the brain to recover

from injuries and disease. Through international collaboration he has proposed

a nutritional protocol for dementia reversal and has recently had a breakthrough

theory on the pathology of dementia. His current aim is to lead the field of

dementia to a new direction of research and treatment of this devastating disease.

e:

philip.mcmillan@nhs.net